Health Care [ 2/12 ] | Biotechnology [ 6/75 ]
NASDAQ | Common Stock
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.
Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 26 | -1.08 Decreased by -33.33% | -0.96 Decreased by -12.99% |
| Nov 5, 25 | -0.34 Increased by +70.55% | -0.95 Increased by +64.33% |
| Aug 6, 25 | -1.00 Increased by +1.96% | -1.00 |
| May 6, 25 | -0.87 Decreased by -10.00% | -1.10 Increased by +21.00% |
| Feb 25, 25 | -0.81 Increased by +40.00% | -1.04 Increased by +22.43% |
| Nov 11, 24 | -1.15 Decreased by -5.93% | -1.06 Decreased by -8.92% |
| Aug 8, 24 | -1.02 Increased by +19.69% | -0.89 Decreased by -14.61% |
| May 8, 24 | -0.79 Increased by +50.93% | -1.10 Increased by +28.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 132.00 K Increased by +83.33% | -120.36 M Decreased by -50.96% | Decreased by -91.18 K% Increased by +17.66% |
| Sep 30, 25 | 70.57 M Increased by +81.96 K% | -34.60 M Increased by +54.88% | Decreased by -49.03% Increased by +99.95% |
| Jun 30, 25 | 75.00 K Increased by +4.17% | -100.73 M Decreased by -54.99% | Decreased by -134.31 K% Decreased by -48.79% |
| Mar 31, 25 | 72.00 K Increased by 0.00% | -86.91 M Decreased by -79.04% | Decreased by -120.71 K% Decreased by -79.04% |
| Dec 31, 24 | 72.00 K Increased by 0.00% | -79.72 M Decreased by -19.24% | Decreased by -110.73 K% Decreased by -19.24% |
| Sep 30, 24 | 86.00 K Increased by +19.44% | -76.69 M Decreased by -60.91% | Decreased by -89.17 K% Decreased by -34.71% |
| Jun 30, 24 | 72.00 K Increased by 0.00% | -64.99 M Decreased by -18.03% | Decreased by -90.27 K% Decreased by -18.03% |
| Mar 31, 24 | 72.00 K Decreased by -26.53% | -48.54 M Increased by +28.77% | Decreased by -67.42 K% Increased by +3.05% |